Abstract

Health care systems worldwide are experiencing tremendous financial pressure because of the introduction of new targeted health technologies and medicines. This study aims to analyze and compare public and household healthcare expenditures in Bulgaria during the period 2015–2019, as well as present the major cost-containment measures implied by the government and their probable influence on the overall health care cost. Regulatory analysis of the endorsed cost-containment measures, budget analysis of public and household health care expenditures, and their extrapolations were performed. The regulatory analysis reveals that a large number of measures are introduced and valid until January 2021, considering pharmaceuticals, medical devices, and negotiations between the National Health Insurance Fund (NHIF) and Marketing authorization holders (MAHs). NHIF costs due to pharmaceuticals, food supplements, and medical devices are rising from 2015 to 2019. The overall health expenditures average per household and the average per person also grow in this period. The cost extrapolation reveals that an increase in 3-year periods is expected. Despite the implementation of variety of cost-containment measures in Bulgaria, such as HTA, ERP, discounts, and annual negotiations, The National Health Insurance Fund's (NHIF) spending on pharmaceuticals continues to rise in recent years, and further increases are expected in the next 3 years. The average expenditure per household and per person also increased, which confirms the global trend of rising medicine and outpatient services value.

Highlights

  • EU countries spent about 9.6% of their GDP on healthcare in 2017

  • This study aims to analyze and compare public and household healthcare expenditures in Bulgaria during the period 2015–2019, as well as present the major cost-containment measures implied by the government and their probable influence on the overall health care cost

  • The cost-containment measures endorsed until January 2021 mainly cover National Health Insurance Fund (NHIF) expenditures for pharmaceuticals, medical devices, and dietetic food (Table 2)

Read more

Summary

Introduction

EU countries spent about 9.6% of their GDP on healthcare in 2017. Switzerland spent the largest share (12.3%), and Turkey the lowest with 4.2%. Among EU countries, Germany spent the most on pharmaceuticals per capita (EUR 572), whereas in Ireland it is EUR 498, and in Belgium it is EUR 491. These countries spent nearly 20% more than the average EU rate. Denmark (EUR 203), Romania (EUR 255), Estonia (EUR 262), and Poland (EUR 267) spent less on pharmaceuticals per capita [1]. Despite the implementation of a variety of cost-containment measures worldwide, pharmaceutical expenditures continue to rise. Despite some evidence from Germany, Portugal, Italy, and France, pharmaceutical expenditure capping and payback mechanisms might lead to cost savings [3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call